Określenie przyczyn hospitalizacji pacjentów z migotaniem przedsionków – dlaczego jest tak ważne? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2015
Słowa kluczowe:
migotanie przedsionków, koszty leczenia, czynniki ryzyka, przyczyny hospitalizacji, choroby współistniejące
##plugins.themes.bootstrap3.article.main##
Abstrakt
Migotanie przedsionków (MP) jest najczęstszym rodzajem zaburzeń rytmu serca w praktyce klinicznej. Bardzo wyraźny wzrost zachorowań w ostatnich latach nakazuje zwrócić szczególną uwagę na tę arytmię. Stanowi ona kosztowny problem społeczny, a leczenie jest obciążające dla budżetu szpitalnego. Wysokie koszty leczenia wynikają z częstych hospitalizacji i procedur wewnątrzszpitalnych. W celu ich zmniejszenia konieczne jest poznanie przyczyn hospitalizacji pacjentów z tą arytmią i tym samym poznanie chorób jej towarzyszących.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Trelewicz-Sosnowska , J. (2015). Określenie przyczyn hospitalizacji pacjentów z migotaniem przedsionków – dlaczego jest tak ważne? . Kardiologia W Praktyce, 9(3), 48-52. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1339
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Charlemagne A., Blacher J., Cohen A. et al.: Epidemiology of atrial fibrillation in France: Extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch of Cardiovascular Disease 2011; 104: 115-124.
2. Keech M., Punekar Y., Choy A.: Trends in atrial fibrillation hospitalisation in Scotland: an increasing cost burden. Br. J. Cardiol. 2012; 19: 173-177.
3. Le Heuzey J.Y.: Hospitalization: a relevant endpoint in atrial fibrillation management? Europace 2011; 13: 1061-1062.
4. Kirchhof P., Ammentorp B., Harald D. et al.: Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidlines on atrial fibrillation: primary results of the PREvention of thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14.
5. Meinertz T., Kirch W., Rosin L. et al.: Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin. Res. Cardiol. 2011; 100(10): 897-905.
6. Steg P.G., Alam S., CE Chiang et al.: Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 2012; 98: 195-201.
7. Johnson B.H., Smoyer-Tomic K., Huse D. et al.: Readmission among hospitalized patients with nonvalvular atrial fibrillation. American Journal of Health-System Pharmacy 2013; 70: 414-422.
8. Hersi A.S., Alsheikh-Ali A.A., Zubaid M et al.: Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review. J. Saudi Heart Assoc. 2012; 24: 243-252.
9. Savelieva I., Camm A.J.: ‘Preferred’ management of atrial fibrillation in Europe. Europace 2014; 16: 1-3.
10. Le Heuzey J.Y., Breithardt G., Camm J. et al.: The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am. J. Cardiol. 2010; 105(5): 687-693.
11. Cohen A., Dallongeville J., Durand-Zaleski I. et al.: Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch. Cardiovasc. Dis. 2010; 103(6-7): 376-387.
12. Chiang C.E., Naditch-Brûlé L., Murin J. et al.: Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythm. Electrophysiol. 2012; 5(4): 632-639.
13. Bonnemeier H., Bosch R.F., Kohlhaussen A.: Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Curr. Med. Res. Opin. 2011; 27(5): 995-1003.
14. Hohnloser S.H., Connolly S.J., van Eickels M. et al.: Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 2009; 360(7): 668-678.
15. Christiansen C.B., Olesen J.B., Gislason G. et al.: Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study. BMJ Open 2013; 3: e001800.
16. Opolski D., Kosior D., Kurzelewski M. et al.: One-year follow-up of the Polish subset of the RecordAF registry of patients with newly diagnosed atrial fibrillation. Pol. Arch. Med. Wew. 2013; 123(5): 238-245.
17. Opolski G., Kosior D., Kurzelewski M. et al.: Baseline characteristics of patients from Poland enrolled in the global registry of patients with recently diagnosed atrial fibrillation (RecordAF), Kardiol. Pol. 2010; 68: 546-554.
18. Rienstra M., McManus D.D., Benjamin E.J.: Novel risk factors for atrial fibrillation: Useful for risk prediction and clinical decision making? Circulation 2012; 125(20): e941-e946.
19. Bosch R.F., Kirch W., Theuer J.D. et al.: Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. Int. J. Cardiol. 2013; 167(3): 750-756.
2. Keech M., Punekar Y., Choy A.: Trends in atrial fibrillation hospitalisation in Scotland: an increasing cost burden. Br. J. Cardiol. 2012; 19: 173-177.
3. Le Heuzey J.Y.: Hospitalization: a relevant endpoint in atrial fibrillation management? Europace 2011; 13: 1061-1062.
4. Kirchhof P., Ammentorp B., Harald D. et al.: Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidlines on atrial fibrillation: primary results of the PREvention of thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14.
5. Meinertz T., Kirch W., Rosin L. et al.: Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin. Res. Cardiol. 2011; 100(10): 897-905.
6. Steg P.G., Alam S., CE Chiang et al.: Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 2012; 98: 195-201.
7. Johnson B.H., Smoyer-Tomic K., Huse D. et al.: Readmission among hospitalized patients with nonvalvular atrial fibrillation. American Journal of Health-System Pharmacy 2013; 70: 414-422.
8. Hersi A.S., Alsheikh-Ali A.A., Zubaid M et al.: Prospective observational studies of the management and outcomes in patients with atrial fibrillation: A systematic review. J. Saudi Heart Assoc. 2012; 24: 243-252.
9. Savelieva I., Camm A.J.: ‘Preferred’ management of atrial fibrillation in Europe. Europace 2014; 16: 1-3.
10. Le Heuzey J.Y., Breithardt G., Camm J. et al.: The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am. J. Cardiol. 2010; 105(5): 687-693.
11. Cohen A., Dallongeville J., Durand-Zaleski I. et al.: Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch. Cardiovasc. Dis. 2010; 103(6-7): 376-387.
12. Chiang C.E., Naditch-Brûlé L., Murin J. et al.: Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythm. Electrophysiol. 2012; 5(4): 632-639.
13. Bonnemeier H., Bosch R.F., Kohlhaussen A.: Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Curr. Med. Res. Opin. 2011; 27(5): 995-1003.
14. Hohnloser S.H., Connolly S.J., van Eickels M. et al.: Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 2009; 360(7): 668-678.
15. Christiansen C.B., Olesen J.B., Gislason G. et al.: Cardiovascular and non-cardiovascular hospital admissions associated with atrial fibrillation: a Danish nationwide, retrospective cohort study. BMJ Open 2013; 3: e001800.
16. Opolski D., Kosior D., Kurzelewski M. et al.: One-year follow-up of the Polish subset of the RecordAF registry of patients with newly diagnosed atrial fibrillation. Pol. Arch. Med. Wew. 2013; 123(5): 238-245.
17. Opolski G., Kosior D., Kurzelewski M. et al.: Baseline characteristics of patients from Poland enrolled in the global registry of patients with recently diagnosed atrial fibrillation (RecordAF), Kardiol. Pol. 2010; 68: 546-554.
18. Rienstra M., McManus D.D., Benjamin E.J.: Novel risk factors for atrial fibrillation: Useful for risk prediction and clinical decision making? Circulation 2012; 125(20): e941-e946.
19. Bosch R.F., Kirch W., Theuer J.D. et al.: Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. Int. J. Cardiol. 2013; 167(3): 750-756.